-
03:45:35 AM

EOLS Stock News

01/28/23 8:00 AM
Nasdaq : EOLS
"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance
Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today presented interim data from its Phase II clinical study evaluating an "extra-strength" formulation for extended duration of Jeuveau ®, its flagship neurotoxin product, at the 2023 International Master Course on Aging Science...
RHEA-AI
neutral
01/23/23 8:00 AM
Nasdaq : EOLS
conferencesclinical trial
Evolus to Present Phase 2 Interim Data from Jeuveau® “Extra-Strength” Dose for Extended Duration Study at 2023 IMCAS World Congress
Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, will present interim findings from a Phase 2 study evaluating the safety, efficacy and duration of effect for its“ extra-strength” dose of Jeuveau ®– the company’ s flagship neurotoxin product– at the 2023 International Master Course on...
RHEA-AI
neutral
01/18/23 8:45 AM
Nasdaq : EOLS
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration
Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced its preliminary, unaudited net revenue as of and for the fourth quarter and full-year ended December 31, 2022. This helped drive sales growth well above the projected growth rate of our industry, making Jeuveau ® the...
RHEA-AI
very positive